Digital reminders to increase flu vaccination in people with heart failure
Tests phone calls and text reminders to encourage flu shots in adults with heart failure.
Key facts
- Who runs it
- Heart Health Research Center
- Where
- Ruyang, ChinaSee the site
- Trial code
- Registry title
- Sequential Digital Intervention to Increase Influenza Vaccination in Patients With Heart Failure
- Status
- Not yet recruiting
- People taking part
- 588 people, planned
- Started
- 15 Oct 2026
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Routine Influenza Vaccination Recommendation
- Repeated AI-Assisted Telephone Intervention
- Gain-Framed SMS Reminder
- Loss-Framed SMS Reminder
- Record updated
- 19 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people who took part in the PANDA II trial and have not yet had this season's flu vaccine. It tests phone calls and text messages to raise flu vaccination.
- Age
- 18 years or older
- Sex
- Men and women can join
- Earlier treatment
- Must not have had the 2026-2027 flu vaccine at the first phone check. Must have taken part in the PANDA II trial.
Main reasons for not taking part
- Already had the 2026-2027 flu vaccine before or at the first phone check
- Could not be reached by phone after the planned attempts
- Flu vaccination status could not be found out at the first phone check
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Previous participation in the PANDA II randomized clinical trial
- Confirmed to be alive at the initial artificial intelligence (AI)-assisted telephone assessment
- Successful telephone contact with sufficient information to determine current-season influenza vaccination status
- Not having received the 2026-2027 seasonal influenza vaccine at the time of the initial telephone assessment
Who cannot take part
- Receipt of the 2026-2027 seasonal influenza vaccine before or at the initial telephone assessment
- Unable to establish effective telephone contact after prespecified contact attempts
- Unable to ascertain current-season influenza vaccination status during the initial telephone assessment; Eligibility for Second-Stage Randomization:; Among participants assigned to the sequential digital intervention group, those who complete the third AI-assisted telephone assessment and remain unvaccinated against seasonal influenza will be eligible for second-stage randomization. Participants who have been vaccinated, cannot be successfully contacted, or have an undetermined vaccination status at the third assessment will not undergo second-stage randomization
Where in China
- Ruyang Rural Health InstituteRuyang, ChinaContact: Yanna SongNo longer taking part
About the trial
What the trial wants to find out
Influenza vaccination is an important preventive measure for patients with heart failure (HF), but vaccination uptake remains low in China. Although previous studies have demonstrated the benefits of actively promoting influenza vaccination, scalable strategies to improve vaccination uptake among patients with HF after hospital discharge remain insufficiently evaluated.
Read full original descriptionShow less
The PANDA-BOOST trial is a prospective, pragmatic, open-label, two-stage sequential randomized clinical trial involving participants previously enrolled in the PANDA II trial. The study aims to evaluate whether sequential digital interventions using artificial intelligence (AI)-assisted telephone calls and short message service (SMS) reminders improve influenza vaccination uptake compared with a single routine vaccination recommendation.
After an initial AI-assisted telephone call providing a standardized influenza vaccination recommendation, eligible unvaccinated participants will be randomized in a 1:2 ratio to a routine recommendation group or a sequential digital intervention group. Participants in the sequential intervention group will receive additional AI-assisted telephone calls approximately 14 and 28 days after the initial call. Those who remain unvaccinated and meet eligibility criteria at the third call will undergo a second randomization in a 1:1:1 ratio to no additional SMS, gain-framed SMS, or loss-framed SMS.
The primary outcome is influenza vaccination uptake within two months after the first-stage randomization.
The 4 groups in the trial
- Routine Recommendation OnlyExisting treatment, for comparison
All participants receive an initial AI-assisted telephone assessment and a standardized influenza vaccination recommendation before first-stage randomization. Participants assigned to the routine recommendation strategy receive no additional study-specific vaccination promotion interventions after randomization.
Treatment: Routine Influenza Vaccination Recommendation
- Sequential AI / No Additional SMSTreatment being tested
Participants assigned to the sequential digital intervention strategy are scheduled to receive additional AI-assisted telephone calls approximately 14 and 28 days after the initial call, subject to protocol-defined stopping rules. Participants confirmed to have been vaccinated discontinue further vaccination promotion. Only participants who complete the third telephone assessment and remain unvaccinated undergo second-stage randomization. Those assigned to the no additional SMS strategy receive no study-specific SMS reminder. Participants who do not undergo second-stage randomization remain in the first-stage intention-to-treat population.
Treatment: Repeated AI-Assisted Telephone Intervention
- Sequential AI / Gain-Framed SMSTreatment being tested
Participants assigned to the sequential digital intervention strategy are scheduled to receive additional AI-assisted telephone calls approximately 14 and 28 days after the initial call, subject to protocol-defined stopping rules. Participants confirmed to have been vaccinated discontinue further vaccination promotion. Only participants who complete the third telephone assessment and remain unvaccinated undergo second-stage randomization. Those assigned to the gain-framed SMS strategy receive one gain-framed vaccination reminder approximately 14 days after second-stage randomization. Participants who do not undergo second-stage randomization remain in the first-stage intention-to-treat population.
Treatment: Repeated AI-Assisted Telephone Intervention and Gain-Framed SMS Reminder
- Sequential AI / Loss-Framed SMSTreatment being tested
Participants assigned to the sequential digital intervention strategy are scheduled to receive additional AI-assisted telephone calls approximately 14 and 28 days after the initial call, subject to protocol-defined stopping rules. Participants confirmed to have been vaccinated discontinue further vaccination promotion. Only participants who complete the third telephone assessment and remain unvaccinated undergo second-stage randomization. Those assigned to the loss-framed SMS strategy receive one loss-framed vaccination reminder approximately 14 days after second-stage randomization. Participants who do not undergo second-stage randomization remain in the first-stage intention-to-treat population.
Treatment: Repeated AI-Assisted Telephone Intervention and Loss-Framed SMS Reminder
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Sequential Digital Intervention to Increase Influenza Vaccination Uptake in Patients With Heart Failure: The PANDA-BOOST Randomized Clinical Trial
- Plain-language title
- Digital reminders to increase flu vaccination in people with heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 19 October 2026